foslevodopa/foscarbidopa vs Parcopa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
foslevodopa/foscarbidopa · Vyalev
Marketed by AbbVie
NCT04380142 · Phase 3 · completed
The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).
Reported efficacy
Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)
Result source: NCT04380142
Parcopa
Rights held by UCB; US product discontinued
NCT00139867 · Phase 3 · completed
The study used randomization and a conventional carbidopa/levodopa comparator, but it was open-label and focused on treatment preference rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Onset of action: time to a 30% decrease in UPDRS Motor Exam (Part III) total score after identical doses of Parcopa and Sinemet: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)
Result source: NCT00139880
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | foslevodopa/foscarbidopa | Parcopa |
|---|---|---|
| OFF time, change | -2.8 vs -1.0vs LD/CDNCT04380142 | —Not posted · NCT00139880 |
| ON time without troublesome dyskinesia, change | 2.7 vs 1.0vs LD/CDNCT04380142 | —Not posted · NCT00139880 |
| UPDRS Part III, change | —Not posted · NCT04379050 | —Not posted · NCT00139880 |
| MDS-UPDRS Part II, change | -2.6 vs -1.1vs LD/CDNCT04380142 | —Not posted · NCT00139880 |
OFF time, change
- foslevodopa/foscarbidopa
- -2.8 vs -1.0vs LD/CDNCT04380142
- Parcopa
- —Not posted · NCT00139880
ON time without troublesome dyskinesia, change
- foslevodopa/foscarbidopa
- 2.7 vs 1.0vs LD/CDNCT04380142
- Parcopa
- —Not posted · NCT00139880
UPDRS Part III, change
- foslevodopa/foscarbidopa
- —Not posted · NCT04379050
- Parcopa
- —Not posted · NCT00139880
MDS-UPDRS Part II, change
- foslevodopa/foscarbidopa
- -2.6 vs -1.1vs LD/CDNCT04380142
- Parcopa
- —Not posted · NCT00139880
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. foslevodopa/foscarbidopa: 4 of 4 rows · Parcopa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | foslevodopa/foscarbidopa | Parcopa |
|---|---|---|
| Dropout rate | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 42.5%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 35.9%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 22.1%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 17.6%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 8.1% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results25.8%ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 27.4%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 24.4%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 0%a NCT00590122 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | infusion site erythema 27% infusion site pain 25.7% infusion site cellulitis 17.6% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more resultsinfusion site erythema 52% infusion site nodule 28.7% infusion site oedema 19.3% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 high dose infusion site erythema 55.8% infusion site nodule 30.1% infusion site oedema 24.8% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 low dose infusion site erythema 48.9% infusion site nodule 27.5% infusion site cellulitis 19.1% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
foslevodopa/foscarbidopa
show 17 more results
show 17 more results
show 17 more results
show 29 more results
+ 6 further endpoints in the CSV export.
Parcopa
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Parcopa's landscape